Company intelligence / Profile preview

ReHeva Biosciences

Dublin, Ohio, United Statesrehevabiosciences.com ↗

Ownership: Private
Development stage: Other

Overview

The company has successfully completed a Phase I safety and tolerability trial of its lead candidate RH324 in patients with advanced NSCLC who have failed prior treatments. The trial demonstrated safety at escalating doses and set the stage for upcoming efficacy studies. No major adverse events reported; further clinical data pending from planned Phase II studies.

Therapeutic areas: Oncology
Modalities: Botanical drugs (naturally occurring complex botanicals)
Industry: Biotech

Drug pipeline

1 asset

RH324

Partnerships

Case Comprehensive Cancer Center University Hospitals & Case Western Reserve University – clinical trial collaboration80 Acres Farms – supply of high-quality botanical raw materials via vertical farming partnership

Beyond the preview

Go deeper on ReHeva Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReHeva Biosciences.